癌補助療法薬剤の世界市場:薬物クラス別

◆英語タイトル:Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026
◆商品コード:GV9NV136
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2019年6月
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥618,800見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥722,800見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥930,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、癌補助療法薬剤の世界市場について調査・分析し、市場動向、薬物クラス別(G-CSF、エリスロポエチン刺激剤(ESA)、制吐剤、ビスホスホネート、オピオイド、NSAIDおよびその他)分析、地域別分析、競合分析などを含め次の構成でお届け致します。

・調査手法及び範囲
・エグゼクティブサマリー
・市場動向
・癌補助療法薬剤の世界市場:薬物クラス別(G-CSF、エリスロポエチン刺激剤(ESA)、制吐剤、ビスホスホネート、オピオイド、NSAIDおよびその他)
・癌補助療法薬剤の世界市場:地域別
・競合分析
【レポートの概要】

The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.

Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Further key findings from the report suggest:

• Some of the key market players are Amgen, Merck, Novartis, Johnson & Johnson, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen led the global cancer supportive care market in 2018, capturing over 30% market share

• By therapeutic class, the global ESAs market for CIA was valued at USD 1,838 million in 2018 and is expected to decline with a CAGR of 6.0% over the forecast period. The biologics segment is anticipated to lose its market share due to patent expiration of major brands such as Epogen

• North America led the cancer supportive care drugs market in 2018 and is expected to maintain its position during the forecast period

• Asia Pacific is expected to witness lucrative growth over the forecast period, owing to improvements in healthcare infrastructure and increasing government initiatives

• Late stage pipeline products include non-opioids such as Tanezumab and HTX-011. Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.2 Research Methodology
1.3 Research Scope and Assumptions
1.4 List to Data Sources
1.5 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/ Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, by Stage
3.4 Clinical Profiles of Disruptive Drugs
3.5 Regulatory Framework
3.6 Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Growing cancer prevalence and increase in number of people receiving chemotherapy
3.6.1.2 Large number of side effects associated with the cancer treatment
3.6.1.3 Fundamental shift from branded biologics to biosimilar domination in cancer associated treatment
3.6.2 Market Restraint Analysis
3.6.2.1 Rising popularity of targeted therapies for the treatment of cancer in developed countries
3.6.2.2 Unmet needs in cancer supportive care
3.6.2.3 Safety issues associated with supportive care agents
3.7 Patent Expiry Analysis
3.8 Cancer Supportive Care Drugs Market: Market Analysis Tools
3.8.1 Industry Analysis – Porter’s
3.8.2 major deals & strategic alliances analysis
3.8.2.1 Joint Ventures
3.8.2.2 Mergers & Acquistions
3.8.2.3 Licensing & Partnership
3.8.2.4 technology collaborations
3.8.3 MARKET Dynamics and Brand STRATEGIES
Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, by Drug Class, 2015 – 2026 (USD Million)
4.1 Definitions & Scope
4.2 Drug Class Market Share Analysis, 2018 & 2026
4.3 Segment Dashboard
4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following
4.4.1 G-CSFs
4.4.1.1 G-CSFs market, 2015 – 2026 (USD Million)
4.4.2 Erythropoietin Stimulating Agents (ESA)
4.4.2.1 Erythropoietin Stimulating Agents market, 2015 – 2026 (USD Million)
4.4.3 Antiemetics
4.4.3.1 Antiemetics market, 2015 – 2026 (USD Million)
4.4.4 Bisphosphonates
4.4.4.1 Bisphosphonates market, 2015 – 2026 (USD Million)
4.4.5 Opioids
4.4.5.1 opioids market, 2015 – 2026 (USD Million)
4.4.6 NSAIDs and Others
4.4.6.1 NSAIDs and Others market, 2015 – 2026 (USD Million)
Chapter 5 Cancer Supportive Care Drugs Market: Regional Market Analysis
5.1 Regional Market Share Analysis, 2018 & 2026
5.2 Regional Market Dashboard
5.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.3.1 North america
5.3.2 Europe
5.3.3 Asia pacific
5.3.4 Latin America
5.3.5 Middle east & africa
5.4 Market Size & Forecasts, Estimates and Trend Analysis, 2018 to 2026
5.5 North America
5.5.1 North america cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.1.1 U.S.
5.5.1.2 U.S. cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.1.3 Canada
5.5.1.4 Canada cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.2 Europe cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.2.1 U.K.
5.5.2.2 U.K. cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.2.3 Germany
5.5.2.4 Germany cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.2.5 France
5.5.2.6 France cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.2.7 Italy
5.5.2.8 Italy cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.2.9 Spain
5.5.2.10 Spain cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.3 Asia Pacific cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.3.1 CHINA
5.5.3.2 China cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.3.3 India
5.5.3.4 India cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.3.5 Japan
5.5.3.6 Japan cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.3.7 Thailand
5.5.3.8 Thailand cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.3.9 South Korea
5.5.3.10 South Korea cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.4 Latin America cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.4.1 Brazil
5.5.4.2 Brazil cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.4.3 Mexico
5.5.4.4 Mexico cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.4.5 Argentina
5.5.4.6 Argentina cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.4.7 Colombia
5.5.4.8 Colombia cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.5 Middle east & Africa cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.5.1 South Africa
5.5.5.2 South Africa cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.5.3 Saudi Arabia
5.5.5.4 Saudi Arabia cancer supportive care drugs market, 2015 – 2026 (USD Million)
5.5.5.5 UAE
5.5.5.6 UAE cancer supportive care drugs market, 2015 – 2026 (USD Million)
Chapter 6 Cancer Supportive Care Drugs Market – Competitive Analysis
6.1 Recent Developments & Impact analysis, by key market participants
6.2 Company Categorization
6.2.1 Market Leader
6.2.2 Key innovators
6.2.3 Emerging Players
6.2.3.1 Pfizer (Hospira)
6.2.3.2 Heron Therapeutics
6.2.3.3 Spectrum Pharmaceuticals
6.2.3.4 Myelo Therapeutics
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company market share analysis, 2018
6.4 Key Companies Profiled
6.4.1 Amgen Inc.
6.4.1.1 Company overview
6.4.1.2 Financial Performance
6.4.1.3 product benchmarking
6.4.1.4 recent developments
6.4.2 Merck & Co.
6.4.2.1 Company Overview
6.4.2.2 Financial Performance
6.4.2.3 Product benchmarking
6.4.2.4 Recent developments
6.4.3 Johnson & Johnson SeRvices, Inc.
6.4.3.1 Company Overview
6.4.3.2 Financial Performance
6.4.3.3 Product benchmarking
6.4.3.4 Recent developments
6.4.4 Heron Therapeutics, Inc.
6.4.4.1 Company Overview
6.4.4.2 Financial Performance
6.4.4.3 Product benchmarking
6.4.4.4 Recent developments
6.4.5 NOVARTIS AG
6.4.5.1 Company Overview
6.4.5.2 Financial Performance
6.4.5.3 Product benchmarking
6.4.5.4 Recent developments
6.4.6 TESARO, Inc.
6.4.6.1 Company Overview
6.4.6.2 Financial Performance
6.4.6.3 Product benchmarking
6.4.6.4 Recent developments
6.4.7 F. Hoffmann-La Roche AG
6.4.7.1 Company Overview
6.4.7.2 Financial Performance
6.4.7.3 Product benchmarking
6.4.7.4 Recent developments
6.4.8 HELSINN Healthcare SA
6.4.8.1 Company Overview
6.4.8.2 Product benchmarking
6.4.8.3 Recent developments

List of Tables

Table 1 List of Abbreviation
Table 2 Cancer supportive care market - Therapeutic classes
Table 3 Cancer supportive care R&D pipeline overview
Table 4 Product profile: RN624 (tanezumab)
Table 5 Product profile: Rolontis
Table 6 Product profile: NEPA IV (Fosnetupitant and palonosetron fixed combination)
Table 7 Product profile: Anamorelin
Table 8 Product profile: HTX-011
Table 9 Product profile: Myelo001
Table 10 Most prevalent cancers using chemotherapy and/or radiation therapy as a treatment
option in the U.S. (2016)
Table 11 Patent expiry analysis
Table 12 Major products- G-CSF
Table 13 Major products- Erythropoietin stimulating agents
Table 14 Major products- Antiemetics
Table 15 Major products- Bisphosphonates
Table 16 Major products- Opioids and non-opioid
Table 17 Product Portfolio: Epogen (epoetin alfa)
Table 18 Product Portfolio: Neupogen (filgrastim)
Table 19 Product Portfolio: Aranesp (darbepoetin alfa)
Table 20 Product Portfolio: Neulasta (pegfilgrastim)
Table 21 Product Portfolio: Xgeva (denosumab)
Table 22 Product Portfolio: Emend (aprepitant)
Table 23 Product Portfolio: Procrit/ Eprex (epoetin alfa)
Table 24 Product Portfolio: Sustol (granisetron)
Table 25 Product Portfolio: Cinvanti (aprepitant)
Table 26 Product Portfolio: Zometa (zolederonic acid)
Table 27 Product Portfolio: Zarxio (filgrastim biosimilar)
Table 28 Product Portfolio: Varubi (rolapitant)
Table 29 Product Portfolio: NeoRecormon (epoetin beta)
Table 30 Product Portfolio: Aloxi (palonosetron)

【レポートのキーワード】

癌補助療法薬剤、G-CSF、エリスロポエチン刺激剤(ESA)、制吐剤、ビスホスホネート、オピオイド、NSAID

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[癌補助療法薬剤の世界市場:薬物クラス別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆